Determination of Roxithromycin in Human Plasma by HPLC with Varied Wavelength UV Detector and Relative Bioavailability of Roxithromycin Dispersible Tablets in Healthy Volunteers
CHEN Ri-lai,ZHOU Yan-bin,TIAN Juan,LI Yu-hong,RAN Li-ling,ZUO Ying,DING Jin-song
DOI: https://doi.org/10.3969/j.issn.1672-2981.2007.06.016
2007-01-01
Abstract:Objective To establish an HPLC method for the determination of roxithromycin in human plasma and study the bioequivalence of roxithromycin dispersible tablets in healthy volunteers.Methods Clarithromycin was used as the internal standard.Roxithromycin was extracted from the plasma sample with dichloromethane(including 5%dehydrated alcohol) and separated on a Hypersil BDS C18 column(200 mm ×4.6 mm,5 μm)with a mobile phase consisting of acetonitrile-0.5% ammonium acetate(46∶54,v/v,pH being adjusted to 8.0 with ammonia water),and the flow rate was 1.0 mL·min-1.The elute was detected at 300 nm from 0~6.2 min and 207nm from 6.2~8.0min.Eighteen male volunteers were given 0.3 g roxithromycin dispersible tablets T1,T2 or R according to a random crossover design.Plasma samples were obtained and determined by the newly-developed HPLC method,and then the pharmacokinetics and bioavailability were studied.Results Roxithromycin was separated well from the endogenous substance,and the regressive curve was linear(r=0.999 2) within the range of 0.25 μg·mL-1 to 32.0 μg·mL-1.The recoveries were within 96.9%~107.6%(n=15),and the inter-day and intra-day RSD were less than 6.4%(n=15) and 4.3%(n=15) respectively.The main pharmacokinetics of T1,T2 and R were as follows : Cmax was(12.4±10.6),(13.4±4.8) and (13.7±3.9) μg·mL-1;Tmax was(1.7±0.3),(1.8±0.4) and(2.3±0.5) h;AUC0~48 was(158.1±42.6),(157.9±54.2) and(160.1±42.5) μg·h·mL-1.Conclusion The method is simple,sensitive,accurate and reproducible,which is suitable for the study of roxithromycin in vivo.T1,T2 and R are bioequivalent.